TWST
Twist Bioscience Corporation · Healthcare · Medical - Diagnostics & Research
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +8 | 54.73M | $5.62B | +14 | −6 |
| Q1 2026 | 108 | +15 | 51.20M | $2.43B | +20 | −5 |
| Q4 2025 | 92 | -2 | 51.46M | $1.63B | +1 | −3 |
| Q3 2025 | 18 | 0 | 32.97M | $927.70M | +1 | −2 |
| Q2 2025 | 16 | -3 | 28.73M | $1.06B | — | −3 |
| Q1 2025 | 16 | +1 | 15.75M | $618.44M | +2 | −1 |
| Q4 2024 | 15 | 0 | 15.20M | $706.21M | — | — |
| Q3 2024 | 14 | +1 | 11.38M | $514.14M | +2 | −1 |
| Q2 2024 | 13 | — | 12.61M | $621.59M | — | — |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 6.13M | — | $302.06M | 2.7% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 1.43M | — | $70.36M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 1.43M | — | $70.36M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 1.34M | — | $66.13M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 1.34M | — | $66.13M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Baillie Gifford ✦ | 984.30K | — | $48.51M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Baillie Gifford ✦ | 984.30K | — | $48.51M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Baillie Gifford ✦ | 984.30K | — | $48.51M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Baillie Gifford ✦ | 984.30K | — | $48.51M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 782.38K | — | $38.56M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 673.06K | — | $33.17M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 579.23K | — | $28.54M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 276.46K | — | $13.62M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Wellington Management ✦ | 276.46K | — | $13.62M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Norges Bank ✦ (被动) | 239.53K | — | $11.80M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 79.05K | — | $3.90M | 0.1% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 61.43K | — | $3.03M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 61.43K | — | $3.03M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 61.43K | — | $3.03M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 34.75K | — | $1.71M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 4.07K | — | $200,767 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 279 持有人, 76.80M 股份, $3.56B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 854 股 · $120,220
Officer · 669 股 · $93,035
Officer · 1.60K 股 · $222,227
Officer · 1.97K 股 · $273,265
Officer · 1.36K 股 · $189,130
Officer · 4.05K 股 · $562,661
Officer, Director · 6.64K 股 · $923,259
Officer · 14.21K 股 · $1.84M
Officer · 2.00K 股 · $245,162
Officer · 6.30K 股 · $761,860
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论